CITATION REPORT List of articles citing

Resveratrol	• 1 •1 •,	1	1	1 •	C , ,	1 •	1 •	•	
Pagyaratral	1nh1h1te	nongl	cohc	110	tottir	113701	diegoeg	110	rote
Mcg v ci ati ui		HUHAI			ially		uiscasc		Tato

DOI: 10.1186/1471-230x-8-40 BMC Gastroenterology, 2008, 8, 40.

Source: https://exaly.com/paper-pdf/43352573/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
167	Obesity and cardiovascular dysfunction: A role for resveratrol?. 2009 , 3, 1-52	13
166	Ectopic lipids and organ function. 2009 , 20, 50-6	151
165	Metabolic benefits from Sirt1 and Sirt1 activators. 2009 , 12, 431-7	79
164	The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. 2010 , 33, 601-9	44
163	Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. 2010 , 633, 78-84	152
162	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. 2010 , 51, 1567-76	90
161	Resveratrol and liver disease: from bench to bedside and community. 2010 , 30, 1103-14	69
160	The Effect of Citrullus colocynthis Pulp Extract on the Liver of Diabetic Rats a Light and Scanning Electron Microscopic Study. 2010 , 6, 155-163	13
159	Effects of dietary resveratrol supplementation on egg production and antioxidant status. 2010 , 89, 1190-8	52
158	Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. 2010, 5, 403-423	16
157	Exploring the molecular mechanisms underlying the potentiation of exogenous growth hormone on alcohol-induced fatty liver diseases in mice. 2010 , 8, 120	16
156	Vitamin C, resveratrol and lipoic acid actions on isolated rat liver mitochondria: all antioxidants but different. 2010 , 15, 207-16	48
155	Is systemic activation of Sirt1 beneficial for ageing-associated metabolic disorders?. 2010 , 391, 6-10	6
154	Ultrasound imaging in an experimental model of fatty liver disease and cirrhosis in rats. 2010, 6, 6	19
153	Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. 2010 , 9, 78	35
152	Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. <i>Antioxidants and Redox Signaling</i> , 2011 , 15, 1325-65	111
151	Improvement of high-fat diet-induced obesity by a mixture of red grape extract, soy isoflavone and L-carnitine: implications in cardiovascular and non-alcoholic fatty liver diseases. 2011 , 49, 2453-8	29

150	Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. <i>Antioxidants and Redox Signaling</i> , 2011 , 15, 437-45	8.4	47	
149	Protective effects of total glucosides of paeony and the underlying mechanisms in carbon tetrachloride-induced experimental liver injury. 2011 , 7, 604-12		19	
148	Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami. 2011 , 12, 78-86		20	
147	Protective effect of whey proteins against nonalcoholic fatty liver in rats. 2011 , 10, 57		57	
146	A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. <i>Phytotherapy Research</i> , 2011 , 25, 1789-95	6.7	18	
145	Pathogenic obesity and nutraceuticals. 2011 , 70, 426-38		16	
144	Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines. 2011 , 79, 623-34		39	
143	Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. 2012 , 2012, 950693		17	
142	Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. 2012 , 5, 952-62		45	
141	Protective effects of total flavonoids from Litsea coreana on alcoholic fatty liver in rats associated with down-regulation adipose differentiation-related protein expression. 2012 , 40, 599-610		20	
140	Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. 2012 , 107, 202-10		124	
139	Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein. 2012 , 34, 2205-12		23	
138	Sida rhomboidea.Roxb extract alleviates pathophysiological changes in experimental in vivo and in vitro models of high fat diet/fatty acid induced non-alcoholic steatohepatitis. 2012 , 64, 217-24		16	
137	Sirtuin biology and relevance to diabetes treatment. 2012 , 2, 243-257		24	
136	Preventive Effects of Flavonoid Extracts from Ilex hainanensis Merr. on Rats with Hepatic Steatosis Induced by a High-Fat Diet. 2012 , 73, 308-316		6	
135	Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. 2012 , 32, 701-8		70	
134	The Effects of Resveratrol on Diabetes and Obesity. 2012 , 413-430		1	
133	Non-alcoholic steatohepatitis: an overview including treatments with herbals as alternative therapeutics. 2012 , 10, 119-136		10	

132	Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2012 , 18, 2609-18	132
131	Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats. 2012 , 26, 384-92	39
130	The role of mitochondria in insulin resistance and type 2 diabetes mellitus. 2011 , 8, 92-103	362
129	Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. 2012 , 18, 152-60	44
128	Resveratrol in metabolic health: an overview of the current evidence and perspectives. 2013, 1290, 74-82	69
127	High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. 2013 , 62, 1186-95	355
126	Free radical biology for medicine: learning from nonalcoholic fatty liver disease. 2013, 65, 952-968	160
125	Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. 2013 , 29, 562-7	79
124	Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. 2013 , 52, 12-8	45
123	Effect of long term administration of resveratrol on lipid concentration in selected organs and liver histology in rats fed high fructose diet. 2013 , 5, 299-305	17
122	Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. 2013 , 10, 35	148
121	Dietary factors, epigenetic modifications and obesity outcomes: progresses and perspectives. Molecular Aspects of Medicine, 2013 , 34, 782-812	201
120	Targeting sirtuins for the treatment of diabetes. 2013 , 3, 245-257	39
119	Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. 2013 , 12, 125-35	30
118	The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver. <i>Food and Function</i> , 2013 , 4, 1148-84	84
117	Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. 2013 , 3, 88-94	58
116	Immune therapy for nonalcoholic steatohepatitis: are we there yet?. 2013 , 47, 298-307	12
115	Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. 2014 , 2014, 637027	94

114	Regulation of neurons in the dorsal motor nucleus of the vagus by SIRT1. 2014 , 7, 270	2
113	Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. 2015 , 7, 204-12	50
112	Effects of resveratrol and other polyphenols in hepatic steatosis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7366-80	98
111	Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. 2014 , 2014, 648308	33
110	Hepatic inflammation scores correlate with common carotid intima-media thickness in rats with NAFLD induced by a high-fat diet. 2014 , 10, 162	22
109	ATF4 deficiency protects hepatocytes from oxidative stress via inhibiting CYP2E1 expression. 2014 , 18, 80-90	25
108	Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. 2014 , 58, 147-71	63
107	Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. 2014 , 6, 188-98	42
106	4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. 2014 , 5, 21	24
105	Resveratrol does not benefit patients with nonalcoholic fatty liver disease. 2014 , 12, 2092-103.e1-6	198
104	Resveratrol modulates autophagy and NF- B activity in a murine model for treating non-alcoholic fatty liver disease. 2014 , 63, 166-73	98
103	Resveratrol does not increase body fat loss induced by energy restriction. 2014 , 70, 639-46	13
102	Novel insights of dietary polyphenols and obesity. <i>Journal of Nutritional Biochemistry</i> , 2014 , 25, 1-18 6.3	558
101	Overexpression of superoxide dismutase 3 gene blocks high-fat diet-induced obesity, fatty liver and insulin resistance. 2014 , 21, 840-8	20
100	Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. 2014 , 34, 837-43	199
99	Resveratrol preserves mitochondrial function, stimulates mitochondrial biogenesis, and attenuates oxidative stress in regulatory T cells of mice fed a high-fat diet. 2014 , 79, H1823-31	26
98	Polyphenols and Flavonoids in Controlling Non-Alcoholic Steatohepatitis. 2014, 615-623	17
97	Epigenetics in adipose tissue, obesity, weight loss, and diabetes. 2014 , 5, 71-81	123

96	Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. 2014 , 30, 915-9	153
95	The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. 2015 , 114, 796-803	109
94	Nutriepigenomics: Personalized Nutrition Meets Epigenetics. 2015, 313-347	2
93	The Protective Effect of Resveratrol on Concanavalin-A-Induced Acute Hepatic Injury in Mice. 2015 , 2015, 506390	30
92	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. 2015 , 7, 1325-36	116
91	Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats. 2015 , 35, 576-84	47
90	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2015 , 21, 3777-85	82
89	Effect of genetically modified rice producing resveratrol on the soil microbial communities. 2015 , 58, 795-805	3
88	Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. 2015 , 49, 1405-18	182
87	Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action. 2015 , 287, 67-76	23
86	Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. 2016 , 54, 1198-208	25
85	Dual effect of red wine on liver redox status: a concise and mechanistic review. 2015 , 89, 1681-93	8
84	Understanding Interindividual Epigenetic Variations in Obesity and Its Management. 2015, 429-460	3
83	Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. 2015 , 59, 1443-57	105
82	Liver delipidating effect of a combination of resveratrol and quercetin in rats fed an obesogenic diet. 2015 , 71, 569-76	15
81	Effect of resveratrol on experimental non-alcoholic steatohepatitis. 2015 , 95-96, 34-41	30
80	Resveratrol increases CD68+ Kupffer cells colocalized with adipose differentiation-related protein and ameliorates high-fat-diet-induced fatty liver in mice. 2015 , 59, 1155-70	15
79	Camel Milk: Potential Utility as an Adjunctive Therapy to Peg-IFN/RBV in HCV-4 Infected Patients in Egypt. 2015 , 67, 1305-13	13

(2017-2015)

78	The effect of tomato juice supplementation on biomarkers and gene expression related to lipid metabolism in rats with induced hepatic steatosis. 2015 , 54, 933-44		33
77	Can metabolically healthy obesity be explained by diet, genetics, and inflammation?. 2015 , 59, 75-93		55
76	Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?. 2015 , 1852, 1137-44		91
75	The Effects of Resveratrol Supplementation in Overweight and Obese Humans: A Systematic Review of Randomized Trials. 2016 , 14, 323-33		32
74	Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. 2016 , 31, 668-75		13
73	Epigenetics in liver disease: from biology to therapeutics. 2016 , 65, 1895-1905		93
72	Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms. 2016 , 75, 47-60		91
71	Effects of Resveratrol on Receptor for Advanced Glycation End Products (RAGE) Expression and Oxidative Stress in the Liver of Rats with Type 2 Diabetes. <i>Phytotherapy Research</i> , 2016 , 30, 66-71	6.7	51
70	Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. 2016 , 6, 22251		48
69	Epigenetic modification by dietary factors: Implications in metabolic syndrome. <i>Molecular Aspects of Medicine</i> , 2017 , 54, 58-70	16.7	36
68	Does Resveratrol Improve Insulin Signalling in HepG2 Cells?. 2017 , 41, 211-216		8
67	Resveratrol pretreatment reduces circulating inflammatory interleukins in CCl 4 -induced hepatotoxicity rats. <i>Bulletin of Faculty of Pharmacy, Cairo University</i> , 2017 , 55, 319-323	1	5
66	Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. <i>Antioxidants and Redox Signaling</i> , 2017 , 26, 519-541	8.4	213
65	Non-alcoholic fatty liver disease and flavonoids: Current perspectives. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, 17-24	2.4	17
64	Epigenetics in fibrosis. <i>Molecular Aspects of Medicine</i> , 2017 , 54, 89-102	16.7	41
63	Emerging roles of SIRT1 in fatty liver diseases. International Journal of Biological Sciences, 2017, 13, 852	2-86.72	146
62	Resveratrol-Induced Effects on Body Fat Differ Depending on Feeding Conditions. <i>Molecules</i> , 2017 , 22,	4.8	8
61	Isolation of a Quercetin-metabolizing Bacterium 19 🖸 0 from Human Feces. <i>Food Science and Technology Research</i> , 2017 , 23, 145-150	0.8	1

60	Resveratrol, Metabolic Syndrome, and Gut Microbiota. <i>Nutrients</i> , 2018 , 10,	6.7	107
59	Herbal management of hepatocellular carcinoma through cutting the pathways of the common risk factors. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 107, 1246-1258	7.5	28
58	Resveratrol and Protection in Hepatic Steatosis: Antioxidant Effects. 2018, 199-209		1
57	Impact of diet on irinotecan toxicity in mice. <i>Chemico-Biological Interactions</i> , 2018 , 291, 87-94	5	8
56	Maslinic acid protects against obesity-induced nonalcoholic fatty liver disease in mice through regulation of the Sirt1/AMPK signaling pathway. <i>FASEB Journal</i> , 2019 , 33, 11791-11803	0.9	28
55	Natural compounds in the chemoprevention of alcoholic liver disease. <i>Phytotherapy Research</i> , 2019 , 33, 2192-2212	6.7	18
54	Effects of resveratrol supplementation in male Wistar rats undergoing an endurance exercise and acute exercise training. <i>Human Antibodies</i> , 2019 , 27, 257-264	1.3	2
53	Protective effect of resveratrol against hepatic damage induced by heat stress in a rat model is associated with the regulation of oxidative stress and inflammation. <i>Journal of Thermal Biology</i> , 2019 , 82, 70-75	2.9	16
52	Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019 , 46, 545-555	3	11
51	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <i>Nutrients</i> , 2019 , 11,	6.7	14
50	The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. <i>Nutrients</i> , 2019 , 11,	6.7	49
49	Lipid Pathway in Liver Cells and Its Modulation by Dietary Extracts. 2019 , 103-116		O
48	Jaboticaba peel powder and jaboticaba peel aqueous extract reduces obesity, insulin resistance and hepatic fat accumulation in rats. <i>Food Research International</i> , 2019 , 120, 880-887	7	22
47	Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease. <i>Archives of Physiology and Biochemistry</i> , 2019 , 125, 142-149	2.2	22
46	Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2020 , 119, 105667	5.6	39
45	Sirt1-PPARS Cross-Talk in Complex Metabolic Diseases and Inherited Disorders of the One Carbon Metabolism. <i>Cells</i> , 2020 , 9,	7.9	18
44	Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
43	The influence of dietary conditions in the effects of resveratrol on hepatic steatosis. <i>Food and Function</i> , 2020 , 11, 9432-9444	6.1	2

(2020-2020)

42	Anti-cancer properties of specific Chinese herbal medicines for hepatocellular carcinoma treatment. <i>European Journal of Integrative Medicine</i> , 2020 , 101215	1.7	
41	A mechanistic insight of phytoestrogens used for Rheumatoid arthritis: An evidence-based review. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 133, 111039	7.5	4
40	Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 , 66, 307-320	1.6	
39	Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021 , 13,	6.7	24
38	Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies. <i>Nutrients</i> , 2021 , 13,	6.7	12
37	The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. <i>Nutrients</i> , 2021 , 13,	6.7	13
36	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. <i>Life Sciences</i> , 2021 , 271, 119220	6.8	11
35	Obesity and aging: Molecular mechanisms and therapeutic approaches. <i>Ageing Research Reviews</i> , 2021 , 67, 101268	12	15
34	Long-term programming of skeletal muscle and liver lipid and energy metabolism by resveratrol supplementation to suckling mice. <i>Journal of Nutritional Biochemistry</i> , 2021 , 95, 108770	6.3	4
33	Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. <i>Methods in Molecular Biology</i> , 2022 , 2343, 19-35	1.4	2
32	Reactive Oxygen Species (ROS) and Liver Disease Therapy. 2014 , 1809-1838		1
31	What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. <i>PLoS ONE</i> , 2011 , 6, e19881	3.7	327
30	Resveratrol alleviates FFA and CCl4 induced apoptosis in HepG2 cells via restoring endoplasmic reticulum stress. <i>Oncotarget</i> , 2017 , 8, 43799-43809	3.3	22
29	Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. <i>Current Pharmaceutical Design</i> , 2013 , 19, 6064-93	3.3	321
28	Biochemical determination of lipid content in hepatic steatosis by the Soxtec method. <i>World Journal of Gastroenterology</i> , 2010 , 16, 1495-9	5.6	13
27	Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression. <i>World Journal of Gastroenterology</i> , 2016 , 22, 2931-48	5.6	39
26	Resveratrol and liver: A systematic review. <i>Journal of Research in Medical Sciences</i> , 2015 , 20, 797-810	1.6	68
25	Administration of low-dose resveratrol attenuated hepatic inflammation and lipid accumulation in high cholesterol-fructose diet-induced rat model of nonalcoholic fatty liver disease. <i>Chinese Journal of Physiology</i> , 2020 , 63, 149-155	1.6	3

24	Effect of GSTM1-Polymorphism on Disease Progression and Oxidative Stress in HIV Infection: Modulation by HIV/HCV Co-Infection and Alcohol Consumption. <i>Journal of AIDS & Clinical Research</i> , 2013 , 4,	1	10
23	The effects of either resveratrol or exercise on macrophage infiltration and switching from M1 to M2 in high fat diet mice. <i>Journal of Exercise Nutrition & Biochemistry</i> , 2015 , 19, 65-72	1.2	21
22	Effect of Resveratrol on Thioacetamide-induced Liver Damage in Rat Models. <i>Hepatitis Monthly</i> , 2020 , 20,	1.8	1
21	Effects of polygonum cuspidatum containing resveratrol on inflammation in male professional basketball players. <i>International Journal of Preventive Medicine</i> , 2013 , 4, S1-4	1.6	19
20	Preclinical analysis of nonsteroidal anti-inflammatory drug usefulness for the simultaneous prevention of steatohepatitis, atherosclerosis and hyperlipidemia. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 22477-83		11
19	The Impact of Resveratrol Supplementation on Inflammation Induced by Acute Exercise in Rats: Il6 Responses to Exercise. <i>Iranian Journal of Pharmaceutical Research</i> , 2019 , 18, 772-784	1.1	1
18	Hepatoprotective and therapeutic effects of resveratrol: A focus on anti-inflammatory and anti-oxidative activities <i>Fundamental and Clinical Pharmacology</i> , 2021 ,	3.1	4
17	A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease <i>IScience</i> , 2022 , 25, 103890	6.1	O
16	Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis <i>Archives of Physiology and Biochemistry</i> , 2022 , 1-16	2.2	O
15	Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease <i>Antioxidants</i> , 2021 , 11,	7.1	11
14	Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease <i>Biomacromolecules</i> , 2021 ,	6.9	2
13	Literature Review on the Use of Herbal Extracts in the Treatment of Non-Alcoholic Fatty Liver Disease <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022 ,	2.2	
12	Resveratrol ameliorates liver fibrosis induced by nonpathogenic Staphylococcus in BALB/c mice through inhibiting its growth <i>Molecular Medicine</i> , 2022 , 28, 52	6.2	О
11	Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial <i>BMC Cardiovascular Disorders</i> , 2022 , 22, 212	2.3	O
10	Modulation of Oxidative Stress-Induced Senescence during Non-Alcoholic Fatty Liver Disease. <i>Antioxidants</i> , 2022 , 11, 975	7.1	О
9	Epigenetic Aspects and Prospects in Autoimmune Hepatitis. Frontiers in Immunology, 13,	8.4	O
8	Role of bioactive compounds in the treatment of hepatitis: A review. 13,		О
7	The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and meta-analysis of randomized controlled trials.		O

CITATION REPORT

6	Effects of beer, wine, and baijiu consumption on non-alcoholic fatty liver disease: Potential implications of the flavor compounds in the alcoholic beverages. 9,	0
5	A review of edible plant-derived natural compounds for the therapy of liver fibrosis. 2023 , 35, 133-152	O
4	Epigenetic regulations in inflammatory diseases. 2023 , 585-613	0
3	Betulin prevents high fat diet-induced non-alcoholic fatty liver disease by mitigating oxidative stress and upregulating Nrf2 and SIRT1 in rats. 2023 , 322, 121688	O
2	Protective role of resveratrol against VCM-induced hepatotoxicity in male wistar rats. 14,	O
1	Effects of Resveratrol Supplementation and Exercise on Apoptosis, Lipid Profile, and Expression of Farnesoid X Receptor, Liver X Receptor and Sirtuin 1 Genes in the Liver of Type 1 Diabetic Rats. 2022 , 16, 39-46	0